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This report examines differences in risk of myocardial infarction and stroke 
(cardiovascular events) between cyclooxygenase-2 (COX-2) inhibitors rofecoxib, 
celecoxib and valdecoxib, and the traditional nonsteroidal anti-inflammatory agents 
(NSAIDs) naproxen and ibuprofen as well as meloxicam, a preferential COX-2 inhibitor. 
The population studied was the DoD TRICARE beneficiary population of age greater 
than 40 during the study period.  In September of 2004, Rofecoxib, a COX-2 inhibitor 
was removed from the market due to an increased risk of cardiovascular events.  In 
February of 2005, the Food and Drug Administration (FDA) examined the entire class of 
COX-2 inhibitors and recommended that Valdecoxib also be withdrawn from the market.  
According to Department of Defense TRICARE prescription records, COX-2 inhibitor 
prescription numbers were increasing rapidly and more than $7 million was spent on 
these agents alone in July of 2004.  Logistic regression was used to analyze TRICARE 
prescription and diagnosis data from calendar years 2002, 2003, and 2004 for 
cardiovascular event risk comparisons among various NSAIDs.  Rofecoxib, was found to 
have a significantly increased risk of cardiovascular events when compared with all other 
medications in the study, including Valdecoxib.  Odds ratios for comparison with 
Valdecoxib, Celecoxib, Meloxicam, Ibuprofen and Naproxen are: 1.09, 1.14, 1.15, 1.28, 
and 1.23.  Valdecoxib showed a significant increase compared to ibuprofen, naproxen 
and celecoxib (Odds Ratios 1.21, 1.16 and 1.06).  Ibuprofen showed a significantly 
decreased risk relative to all medications except naproxen.  When considering only 
cardiovascular risk, this study suggests prescribers should consider ibuprofen or naproxen 
as the primary agent of choice, with meloxicam, and celecoxib as reasonable second 
choices.  Ultimately, the decision must also weigh the patient’s risk of gastrointestinal 























THIS PAGE INTENTIONALLY LEFT BLANK 
  vii





A. BACKGROUND OF ANTI-INFLAMMATORY AGENTS .......................1 
1. NSAID Actions .....................................................................................1 
2. COX-2 Selective and Preferential Agents..........................................1 
3. DoD  Financial Impact of COX-2 Agents ..........................................2 
B. PROBLEM DESCRIPTION...........................................................................4 
1. Market Withdrawal of Vioxx and Bextra..........................................4 
2. DoD Impact...........................................................................................5 
C. HOW THIS ANALYSIS SUPPORTS PROBLEM RESOLUTION...........5 
II. METHODS ...................................................................................................................7 
A. STUDY POPULATION AND DATA SOURCE...........................................7 
B. NSAID CATEGORIES ...................................................................................7 
C. DATA MANAGEMENT.................................................................................8 
D.  STATISTICAL ANALYSIS ...........................................................................9 
III. RESULTS ...................................................................................................................11 
A. DISTRIBUTION INFORMATION .............................................................11 
1. Medication Distribution ....................................................................11 
2. Event Distribution..............................................................................12 
B. STATISTICAL RESULTS ...........................................................................13 
IV. DISCUSSION .............................................................................................................15 
A. GENERAL DISCUSSION ............................................................................15 
B. PROBLEMS AND LIMITATIONS.............................................................16 
1. Age Restriction...................................................................................16 
2. Confounders .......................................................................................17 
a. Aspirin and Other OTCs.........................................................18 
b. Socioeconomic Factors ...........................................................18 
c. Co-morbid Conditions and Indications..................................18 
d. Intermittent Use.......................................................................19 
3. Event Selection ...................................................................................19 
4. Data Issues ..........................................................................................20 
a. ID Mapping .............................................................................20 
b. Size of Data..............................................................................20 
c. Data Integrity ..........................................................................20 
C. COMPARATIVE STUDIES.........................................................................21 
V. CONCLUSION AND RECOMMENDATIONS.....................................................23 
APPENDIX A. LIST OF ACRONYMS .....................................................................27 
APPENDIX B. FDA DECISION MEMORANDUM................................................29 
APPENDIX C. NUMBER OF PRESCRIPTIONS BY AGE AND DOSING .........47 
  viii
APPENDIX D. ESTIMATED COEFFICIENTS FOR THE LOGISTIC 
REGRESSION MODEL ...........................................................................................49 
INITIAL DISTRIBUTION LIST .........................................................................................51 
 
  ix




Figure 1. MHS NSAID Prescriptions Jul 01-Dec 04 (From Trice 2005)..........................2 
Figure 2. MHS NSAID Expenditures by Point of Service (From Trice 2005) .................3 
Figure 3. MTF NSAID Expenditures by Category (From Trice 2005).............................3 
Figure 4. Number of Prescriptions by Product and Dosage ............................................11 
Figure 5. Age Distribution...............................................................................................12 
Figure 6. Events by Medication ......................................................................................12 
Figure 7. Events by Age ..................................................................................................13 






























THIS PAGE INTENTIONALLY LEFT BLANK 
  xi




Table 1. Dosing designations ...........................................................................................8 
Table 2. Age Bins...........................................................................................................10 
Table 3. Beneficiary Categories.....................................................................................10 






























I would like to thank Professors Buttrey and Whitaker for their assistance with 
this project.  Their experience was invaluable for both data management and 
interpretation of results.  I would also like to thank my husband for his endless support 
and lack of complaints while I was glued to the computer for countless hours.  
Additionally, I would like to thank CDRs Richerson and Graham, LTC Kelly, Roger 
Anderson, Dave Bretzke, and anyone else at the PEC who may have had a hand in 






























In September of 2004 Merck and Co. voluntarily withdrew their non-steroidal 
anti-inflammatory product, Vioxx, from the market due to mounting evidence that it 
placed users at an increased risk of cardiovascular events such as myocardial infarction 
and stroke.  This prompted an extensive review of all non-steroidal anti-inflammatory 
agents by the Food and Drug Administration (FDA), with a subsequent recommendation 
that Pfizer remove its product, Bextra, from the market as well.  Additionally, the FDA 
mandated that all remaining agents carry new and stronger warnings regarding the 
potential for serious adverse cardiovascular events in addition to the warnings of life 
threatening gastrointestinal bleeding. 
At the time Vioxx and Bextra were removed from the market, DoD TRICARE 
beneficiaries were filling more than 60,000 prescriptions per month for Vioxx and 
another 45,000 per month for Bextra.  Military Treatment Facility expenditures were 
more than $7 million per month for Vioxx, Bextra and Celebrex alone.  This cost does 
not include prescriptions obtained from other TRICARE network sources such as retail or 
mail order outlets. 
This study aims to determine differences in cardiovascular risk among the most 
popular non-steroidal anti-inflammatory agents, including those that were removed from 
the market.  Results can be used as part of a complete cost benefit analysis of products in 
this class, and the information used as a basis for safe prescribing. 
The study was performed using TRICARE prescription records from calendar 
years 2002, 2003, and 2004.  Patients of age greater than 40 years who received at least 
one prescription for Motrin (ibuprofen), Vioxx (rofecoxib), Bextra (valdecoxib), 
Celebrex (celecoxib), Naprosyn (naproxen), or Mobic (meloxicam) were entered into the 
study.  All events of myocardial infarction and stroke were also obtained for this same 
period.  Prescription records were cross-matched with the event file and a determination 
was made whether or not to associate an event with a prescription.  A logistic regression 
model was used to determine odds ratios of events among the various prescription 
 medications.  Variables in the following model included the category of the beneficiary, 
age, product, and dosing, which was categorized as either high or low. 




p age med dose bencat
p
β β β β β= + + + +− i  
Upon analysis, rofecoxib (Vioxx), was found to have a significantly increased risk 
of cardiovascular events when compared with all other medications in the study, 
including Valdecoxib (Bextra).  Odds ratios for comparison with Valdecoxib, Celecoxib, 
Meloxicam, Ibuprofen and Naproxen are: 1.09, 1.14, 1.15, 1.28, and 1.23.  Valdecoxib 
showed a significant increase compared to ibuprofen, naproxen and celecoxib (,Odds 
Ratios 1.21, 1.16 and 1.06).  Ibuprofen showed a significantly decreased risk relative to 
all medications except naproxen.  Ninety-five percent confidence intervals are included in 
the full report.   
When considering only cardiovascular risk, this study suggests prescribers should 
consider ibuprofen or naproxen as the primary agent of choice, with meloxicam, and 
celecoxib as reasonable second choices.  Ultimately, the decision must also weigh the 





I. INTRODUCTION  
A. BACKGROUND OF ANTI-INFLAMMATORY AGENTS 
1. NSAID Actions 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective agents commonly 
used for the relief of both acute and chronic pain and inflammatory conditions.  Though 
effective, life-threatening complications from use of traditional NSAIDs, i.e. ibuprofen 
and naproxen, such as gastrointestinal (GI) ulceration, hemorrhage and perforation, led to 
research and development of a sub-class of anti-inflammatory agents called 
cyclooxygenase-2 enzyme (COX-2) inhibitors.  Cyclooxygenase-1 enzyme (COX-1) is 
thought to be a protective factor for the mucosal lining of the gastrointestinal tract and 
normal platelet function while COX-2 is believed to be primarily responsible for 
mediating the inflammatory response and its subsequent pain production.  Since 
traditional NSAIDs produce relief by blocking both COX-1 and COX-2, it was felt that 
GI toxicities may be alleviated by producing agents that could selectively inhibit COX-2 
(Cryer & Feldman, 1998).  The ratios of selectivity and differences of traditional NSAIDs 
have previously been evaluated ex vivo (Cryer & Feldman, 1998) although in vivo studies 
have yet to clearly demonstrate the clinical significance of these differences.  
2. COX-2 Selective and Preferential Agents  
 During pre-clinical testing of rofecoxib (Vioxx), it was noted that COX-2 was 
also produced in endothelial cells of blood vessels initiating concern over a potential for 
harmful cardiovascular effects if inhibited (Weir, Sperling, Reicin, & Gertz, 2003).  This 
concern was not demonstrated to be of significance during initial clinical trials at doses of 
25mg or less, and thus rofecoxib was brought to market (Bull & Seligman, 2005).  
However, concern over cardiac safety has plagued the COX-2 selective inhibitors since 
introduction to the market of rofecoxib and celecoxib (Celebrex) in 1999.  A third agent, 
valdecoxib (Bextra) was added to the market in 2002.  Nevertheless, the safety concern 
was placed in the background as these agents quickly took hold in the marketplace, 
resulting in an estimated total of 105 million prescriptions for rofecoxib alone in the 
United States from May 1999 through August 2004 (Merck, 2005).  Investigators have 
 identified a third category of NSAIDs, containing the agents meloxicam (Mobic) and 
etodolac (Lodine).  This third category is considered to be COX-2 preferential, but 
exhibits more blocking of COX-1 than the selective COX-2 inhibitors, positioning this 
third category of agents as intermediaries between the non-selective and selective 
therapies. 
3. DoD  Financial Impact of COX-2 Agents 
Department of Defense (DoD) healthcare beneficiaries who received prescription 
benefits under the TRICARE program filled approximately 175,000 prescriptions for 
COX-2 agents alone in July of 2004, at a cost of more than $7 million.  Figures 1 and 2 
(From Trice, 2005) indicate a breakdown of NSAID prescriptions filled under the 
TRICARE Military Health System (MHS), and their respective costs according to the 
method by which prescriptions were obtained.  Of particular note are the steadily 
increasing overall NSAID costs in millions of dollars in Figure 2.  These are primarily the 
























































Figure 1.   MHS NSAID Prescriptions Jul 01-Dec 04 (From Trice 2005) 
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Figure 2.   MHS NSAID Expenditures by Point of Service (From Trice 2005) 
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Figure 3.   MTF NSAID Expenditures by Category (From Trice 2005) 
Figure 3 depicts the dramatic increase in expenditures in military treatment 
facility (MTF) budgets due to COX-2 agents.  It does not contain information from 
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prescriptions filled at TRICARE network pharmacies as Figures 1 and 2 do.  On a 
positive note, as expected, COX-2 expenditures dropped significantly following market 
withdrawal of rofecoxib.   
B. PROBLEM DESCRIPTION 
1. Market Withdrawal of Vioxx and Bextra 
On 30 September 2004, Merck & Co., Inc., announced voluntary withdrawal from 
the market of its popular drug rofecoxib due to mounting clinical evidence that it 
increased cardiovascular (CV) risk, that is, risk of stroke or myocardial infarction, when 
compared to placebo or to the risk among individuals not taking such an agent.  Study 
investigators in the Adenomatous Polyp Prevention on Vioxx (APPROVe) trial reported 
preliminary findings that rofecoxib increased the risk for confirmed CV events twofold 
when compared with placebo, and halted the study early (Bull & Seligman, 2005; 
Le vesque, Brophy, & Zhang, 2005).  The CV effects were not evident during the first 18 
months of the APPROVe study and were only evident at the three-year data point 
(Merck, 2005).  Previously, in 2000, Vioxx Gastro Intestinal Outcomes Research Trial 
(VIGOR) investigators reported a reduced risk of severe gastrointestinal toxicity with 
patients treated with rofecoxib, but a greater risk was found for CV thromboembolic 
events in rofecoxib patients versus those treated with naproxen (Bull & Seligman, 2005).  
This study was conducted using a rofecoxib dose of 50mg whereas previous studies using 
a dose of 25mg did not have similar findings.  This resulted in a labeling change for 
Rofecoxib in April of 2002 indicating an increased risk of CV thromboembolic events at 
the 50mg dose, but marketing continued.  
Voluntary withdrawal of rofecoxib following the preliminary results of the 
APPROVe trial prompted an in-depth review of the entire class by the Food and Drug 
Administration (FDA) amid concern of whether the other agents, celecoxib and 
valdecoxib, shared the same risks.  Studies to date have produced conflicting results (Bull 
& Seligman, 2005; Levesque et al., 2005; Solomon et al., 2004).  After significant debate, 
valdecoxib was found to have no advantages over rofecoxib and celecoxib, and possessed 
an increased incidence of a potentially life-threatening skin reaction.  This resulted in an 
unfavorable overall benefit versus risk profile and subsequent FDA recommendation for 
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removal from the market (Appendix B). Valdecoxib was removed from the market as a 
result, leaving celecoxib as the sole COX-2 agent.  Of significance, full recommendations 
from the FDA review also call into question the CV safety of non-selective NSAIDs 
(Appendix B). 
2. DoD Impact 
Withdrawal from the market of two out of three available COX-2 inhibitors and 
strengthened warnings on non-selective NSAIDs raises several questions with respect to 
prescribing habits within the DoD.  First, for patients previously taking one of the now 
unavailable medications, what should they be switched to? Second, since the FDA was 
unable to rank the COX-2 inhibitors and other NSAIDs with respect to cardiovascular 
risk; does the TRICARE data provide evidence to suggest a ranking of medications in 
this category?  Are the studies used by the FDA to evaluate cardiovascular risk of the 
COX-2 agents representative of the DoD population?  How do the cardiovascular risk 
profiles of the COX-2 agents compare to those of the traditional NSAIDs or preferential 
agents?  Given the volume of prescriptions and their associated expenditures, it is 
possible that millions of dollars may be saved by switching patients from rofecoxib or 
valdecoxib to the intermediate meloxicam, instead of the more costly celecoxib, without 
placing patients at an increased CV risk.   
C. HOW THIS ANALYSIS SUPPORTS PROBLEM RESOLUTION 
This study attempts to quantify cardiovascular risks of COX-2 selective agents 
specifically in the DoD TRICARE population when compared with traditional NSAIDs, 
ibuprofen and naproxen, as well as with the preferential COX-2 agent, meloxicam.  The 
DoD prescription volume and cost data necessitate a thorough study of this issue to 
determine recommendations and guidance on how DoD physicians and patients should 
position further use of NSAIDs that remain on the market to minimize both cost and 
patient risk.  The results produced in this report can be used in a complete cost-benefit 
analysis of the NSAID class.  Additionally, there is a possibility that COX-2 agents in 
development will become available in the future.  Hence, clarification of the factors 
associated with increased CV risk in this widely used class of medications is prudent.  
“Cardiovascular effects among the COX-2 inhibitors seem different, but further studies, 
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preferably randomized trials, are needed to fully understand the spectrum of effects of 























A. STUDY POPULATION AND DATA SOURCE 
This study was conducted as a retrospective record review of patients who took 
NSAIDs and experienced a CV event (stroke or MI) compared to those who took 
NSAIDs and did not experience an event.  The population used for this study was all 
TRICARE beneficiaries of age 40 or greater (at the time of first prescription receipt) who 
received one or more prescriptions for the products of interest during the calendar years 
of 2002, 2003, 2004.  Eligible beneficiaries included active duty members, dependents of 
active duty members, retirees and dependents of retirees.  Data were obtained from the 
TRICARE M2 database, accessed by the DoD Pharmacoeconomic Center (PEC) in Fort 
Sam Houston, TX.  A total of 1,523,357 patients were entered into the study.  The 
following items were included in the database: patient ID numbers, patient beneficiary 
category, age, NSAID(s), strength, quantity, date medication was obtained, CV events, 
and their corresponding dates.  CV events were specified as those with Internal 
Classification of Diseases Ninth Revision (ICD-9) codes for acute myocardial infarction 
and stroke in the primary diagnosis field (codes 410.xx and 430.xx-436.xx respectively).  
Patient ID numbers were mapped to a pseudo-ID number by the PEC in order to preserve 
patient privacy.   
B. NSAID CATEGORIES 
Popular medications from each of the three NSAID were selected for comparison.  
In the non-selective category, ibuprofen and naproxen were selected, since these were by 
far the most frequently prescribed and recent questions had arisen with regard to 
cardiovascular risks of both agents (Hippsiley-Cox & Coupland, 2005; Graham et al., 
2005).  Meloxicam was chosen from the intermediate COX-2 preferential category and 
all three COX-2 specific agents, rofecoxib, celecoxib and valdecoxib, were studied.  Each 
medication average daily dosage was defined as either high or low and the a priori 
designations are shown in Table 1.  A priori determinations were established in 
accordance with those used in previous studies (Weir, Sperling, Reicin, & Gertz, 2003; 
Solomon et al., 2004). 
  
Medication Low Dose High Dose 
Rofecoxib 25≤ mg >25 mg 
Celecoxib 200≤ mg >200 mg 
Valdecoxib ≤20 mg >20 mg 
Meloxicam ≤15 mg >15 mg  
Ibuprofen ≤1800 mg >1800 mg 
Naproxen ≤1000 mg >1000 mg 
Table 1. Dosing designations 
 
C. DATA MANAGEMENT 
S-Plus 7.0 Enterprise Edition statistical software was used for all data 
management and analyses (Copyright (c) 1988, 2005 Insightful Corp.).  Raw data was 
initially obtained in five separate files.  The two event files contained patient ID’s and 
information regarding hospital admissions for diagnoses of acute myocardial infarction or 
stroke.  One event file contained information and dates from MTFs and the other 
contained similar information from TRICARE network civilian medical facilities.  These 
files represented all incidents of acute myocardial infarction and stroke in the population 
without regard to NSAID status.  These two event files were combined, and entries with 
missing ID numbers or other missing information were removed, as were those with 
events occurring prior to January 1, 2002, resulting in a total of 93,829 entries from the 
original 120,456.  The other three files, containing prescription information for years 
2002, 2003, and 2004, were merged into one file with a total of 7,955,610 records.  After 
prescription entries with missing information or those prescriptions which were obtained 
following an event were removed the total number of prescription entries was 7,907,970.  
Entries for products that were listed by more than one name were edited so that all names 
for the same product were consistent.  For example, ibuprofen was listed as Motrin, 
Motrin IB or ibuprofen, so all occurrences were changed to “Motrin.”  Average daily 
doses were calculated by multiplying the milligram strength of the product by the 
quantity received and dividing by the days supply.  If there was more than one product 
obtained by an individual, this calculation was done for each product.  The event file IDs 
were screened against the IDs in the prescription file to determine association of an event 
with that particular individual.  This screening resulted in a reduction of entries in the 
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 event file from 93,829 to 33,342 as those individuals having events who did not receive 
prescriptions for NSAIDs were removed.  If the event was more than thirty days 
following the end of any prescription period as determined by days supply, the event was 
not associated with a prescription.  Also, if there was more than one event for a particular 
individual, the first event was used so that there was no more than one event per person.  
When the ID number had more than one product listed, the event was associated with the 
prescription having the closest date to the event but not following.  The final event file, 
consisting of those events considered to be associated with a particular prescription, 
contained 12,023 entries.   
D.  STATISTICAL ANALYSIS 
Analysis was performed using a logistic regression model to estimate odds ratios 
with the response variable being event or no event.  Differences in these ratios and their 
respective confidence intervals were calculated.  Predictor variables and possible 
confounders were: age, medication, dose category, and beneficiary category.  Each of the 
variables was treated as a categorical factor.  The equation describing the model is: 




p age med dose bencat
p
β β β β β= + + + +− i  
where ip  is the probability of an individual having a CV event and i goes from one to k, 
with k being the number of different combinations of factor levels;  age is the age bin of 
the patient, med is the medication he or she was prescribed, dose is the a priori high or 
low designation, and bencat is the beneficiary category. 
The age variable was classified into 12 bins, each spanning 5.5 years.  Since the 
last 3 age bins contained less than 1 percent of the population, they were combined 
resulting in a total of 10 bins.  The bins and percentages of patients in each bin are shown 






 Age Bins (yrs) % 
1 [41.28,46.78) 9.59 
2  [46.78,52.27) 11.53 
3  [52.27,57.77) 11.70 
4 [57.77,63.26) 12.29 
5 [63.26,68.75) 15.12 
6 [68.75,74.25) 16.11 
7  [74.25,79.74) 11.71 
8  [79.74,85.23) 8.36
9  [85.23,90.73) 2.96
10 [90.73,107.21] 0.63
Table 2. Age Bins  
Medication dosage classification is given in Table 1.  The response variable, 
occurrence of a CV event, was coded as a “1,” while absence of an event was coded as a 




DA Dependent of Active Duty
DGR Dependent of Guard/Reserve











 III. RESULTS 
A. DISTRIBUTION INFORMATION 
1. Medication Distribution 
Figure 4 indicates the distribution of prescriptions by product and dosing 
category.  Celecoxib had the largest number of prescriptions dispensed at more than 2.23 
million.  Rofecoxib followed with more than 1.79 million prescriptions, valdecoxib had 
more than 0.7 million prescriptions, while ibuprofen, naproxen and meloxicam recorded 


































Figure 4.   Number of Prescriptions by Product and Dosage 
Of note, ibuprofen prescriptions were dispensed much more consistently at the 
upper limit of the dosing range than any of the other products.  The result of categorizing 
prescriptions by both age and dose according to medication is presented in Appendix C.  
The percentage of COX-2 agents consistently increased with age, ranging from 29.3% for 
the youngest group to 84.5% for the oldest.  The population age distribution is presented 
in Figure 5.  The mean patient age was 64.4 years. 
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Prescriptions by Age  
Figure 5.    Age Distribution 
 
2. Event Distribution 
Raw event rates for each medication and age grouping are given in Figures 6 and 
7 respectively.  Raw event rates increase with age. 































Figure 6.   Events by Medication 
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Figure 7.   Events by Age 
 
 
B. STATISTICAL RESULTS 
The regression model resulted in a residual deviance of 172,742 with 7,907,969 
total and 7,907,945 residual degrees of freedom.  The full model and estimated 
coefficients are listed in Appendix D.  A summary of the results of every pairwise 
comparison of products is given in Table 3.  Odds ratios for comparisons to the base 
medication, valdecoxib, were calculated from the coefficients estimated in the model (see 
Appendix D).  Confidence intervals for the comparisons were calculated using the 
standard errors for the coefficients estimated by the model.  For comparisons not 
involving the base medication, differences in odds were calculated by subtraction of the 
corresponding estimated coefficients.  Confidence intervals for these differences were 
based on standard errors computed from the standard errors of each estimated coefficient 
along with the appropriate correlation coefficient.  Several statistically significant 
differences, marked by bold type in Table 4, were noted among the various agents in the 
study when compared for incidence of cardiovascular events. 
Rofecoxib had a significantly higher risk than all other agents.  Analysis shows 
increased odds of CV events by 23% and 28% for rofecoxib when compared to naproxen 
and ibuprofen respectively.  The results suggest an overall ranking of increasing risk as 
follows: ibuprofen, naproxen, meloxicam, celecoxib, valdecoxib and rofecoxib with not 
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 all differences being significant.  Figure 8 depicts the statistical differences among the 
agents.  Agents underscored by the same bar were not found to be statistically different.  
Note that although meloxicam was not found to be different from either celecoxib or 
valdecoxib, celecoxib and valdecoxib were found to be different from each other.  This 
can be attributed to the difference in sample sizes.  Meloxicam had fewer than 0.45 
million prescriptions, celecoxib had greater than 2 million prescriptions and valdecoxib 
had greater than 0.7 million.  




Figure 8.   Differences 
 
   
Medication OR Lower Limit Upper Limit 
Celecoxib/Valdecoxib 0.936 0.879 0.997
Meloxicam/Valdecoxib 0.930 0.845 1.024
Ibuprofen/Valdecoxib 0.789 0.728 0.854
Naproxen/Valdecoxib 0.843 0.777 0.914
Rofecoxib/Valdecoxib 1.094 1.027 1.165
Celecoxib/Meloxicam 1.006 0.923 1.098
Celecoxib/Ibuprofen 1.187 1.115 1.264
Celecoxib/Naproxen 1.110 1.037 1.189
Celecoxib/Rofecoxib 0.855 0.811 0.890
Meloxicam/Ibuprofen 1.180 1.068 1.303
Meloxicam/Naproxen 1.103 0.998 1.220
Meloxicam/Rofecoxib 0.850 0.779 0.927
Ibuprofen/Naproxen 0.935 0.861 1.016
Ibuprofen/Rofecoxib 0.721 0.674 0.770
Naproxen/Rofecoxib 0.770 0.719 0.825
 





A. GENERAL DISCUSSION 
This study, with 1,523,357 patients, is consistent with the conclusions of recent 
studies (Graham et al., 2005; Kimmel et al., 2005; Levesque et al., 2005) and a meta-
analysis (Juni et al., 2004).  Additionally, the data suggest that the conclusions of prior 
studies in elderly patients can indeed be extended to a younger population.  These results 
also support the suggestion that naproxen may exhibit a cardioprotective effect (Juni et 
al., 2004) with respect to other NSAIDs but not to non-NSAID users).  This suggestion 
was not supported by a previous observational study which did not evaluate dosing 
effects and found no evidence of increased risk for rofecoxib or any other NSAIDs 
(Mamdani et al., 2003).  Also, a study of Medicare beneficiaries reported increased 
relative risk with rofecoxib when compared to celecoxib and use of no NSAIDs, but 
showed no other differences among the other comparisons (Solomon et al, 2004).   
The majority of previous studies have been in elderly (age > 64) or otherwise 
limited populations (Levesque et al., 2005; Mamdani et al., 2003; Nussmeier et al., 2005; 
Solomon et al., 2004) although a few of the most recent have included patients as young 
as 40 and 18 years of age (Graham et al., 2005; Hippisley-Cox & Coupland, 2005; 
Kimmel et al., 2005).  Additionally, the majority have studied only myocardial infarction 
as an endpoint.  Reicin et al. (2002) studied a much broader group of endpoints including 
myocardial infarction, cerebrovascular accidents, and cardiovascular, hemorrhagic and 
unknown death, but rofecoxib was the only COX-2 agent available for study at the time.  
Unfortunately, dose differentiations and duration of treatment were not studied by Reicin, 
and the conclusion was that there were no differences in risk of events among 
medications studied.  These earlier results have since been studied further and the dosing 
risks and length of exposure risks with rofecoxib have become clearer (Bull & Seligman, 
2005).  The preferentially selective agent meloxicam, which few previous studies have 
considered, was included in this current report (Garcia Rodriguez, Varas-Lorenzo, 
Maguire, Gonzalez-Perez, 2004; Levesque et al., 2005).  Garcia Rodriguez et al. (2004) 
compared a variety of non-selective NSAIDs as well as meloxicam and found no 
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difference among any of the agents and risk of MI.  The present study did find a 
difference between meloxicam and ibuprofen.  
Hippisley-Cox and Coupland (2005) reported an increased risk of MI for 
ibuprofen when compared to naproxen, a result which is not supported by the present 
study.  Cryer and Feldman (1998) determined ex vivo that ibuprofen was more selective 
for COX-1 than naproxen and that naproxen was more selective for COX-2, so the 
previously reported increased risk for ibuprofen remains unexplained and unsupported.    
Although gaining a clearer understanding of the risk differences among COX-2 
inhibitors and non-selective NSAIDs may seem to be a moot point since only celecoxib 
remains on the market, development of other anti-inflammatory agents with a reduced 
risk of gastrointestinal side effects is still a desirable goal; thus an improved 
understanding is indeed helpful.        
B. PROBLEMS AND LIMITATIONS 
1. Age Restriction 
The population age was restricted to individuals of age 40 or above due to the 
abundance of NSAID prescriptions for acute conditions and relatively minimal incidence 
of cardiovascular events in younger individuals.  This restriction allowed for study of the 
entire TRICARE population of age greater than or equal to 40.  Inclusion of younger 
patients would have been computationally prohibitive or required a change to a random 
sample or case-control design.  Increased risk of MI with rofecoxib at doses of greater 
than 25 mg/day has previously been established in patients as young as 18 (Graham et al., 
2005; Levesque et al., 2005).  Another recently published article supported an increased 
risk of MI among patients of ages 25 and above taking rofecoxib, ibuprofen or 
diclofenac, versus patients not taking those drugs, but did not elucidate any dosage 
differences (Hippisley-Cox & Coupland, 2005). 
Patient age was calculated for all patients using the date at the end of the study 
period.  Thus, a patient of age 41 entering the study and experiencing an event in 2002 
would be recorded as age 43, while a 41 year old patient entering in 2004 would be 
recorded as 41.  Using the date of birth to calculate an age at the time of each prescription 
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issue may have been a more appropriate calculation and allowed for natural age 
progression throughout the study period.  
Partitioning of age into bins was performed a priori without benefit of a tree or 
partitioning function.  The size of the data precluded use of either of these methods of 
categorization though their use could have improved the model.      
2. Confounders 
This study could not account for all confounders.  Access to data was limited and 
a simple study design was desired.  However, it is likely that beneficiary category acted 
as a surrogate for some of the potential confounders that were not included.  For instance, 
active duty service members are generally healthier than individuals not serving on active 
duty.  When significance of the variable beneficiary category was tested by running the 
model without that variable, a p-value of essentially zero indicated that the model 
including the variable was preferred.  The residual deviance difference was 501 with a 
difference of 9 degrees of freedom.   
Gender was only available in the event file and not in the prescription file, so this 
potential effect was not available for inclusion.  Interestingly, this study achieved results 
similar to other studies with more complex designs intended to account for as many 
confounders as possible (Graham et al., 2005; Hippisley-Cox & Coupland, 2005; 
Solomon et al., 2004).  Although Graham et al. (2005) found increased risk of MI with 
rofecoxib, they did not find a decreased risk with naproxen or ibuprofen (with respect to 
non-NSAID users) nor did Hippisley-Cox & Coupland (2005).  Co-morbid conditions 
and medications, both prescription and over-the-counter (OTC), were not considered in 
this analysis, nor were smoking status, obesity, race, family history, physical activity or 
socioeconomic status.  This may have introduced bias to the results since theoretically 
patients taking COX-2 inhibitors were at a higher risk of GI bleeding complications and 
thus in generally poorer health.  This effect was possibly mitigated somewhat by taking 
age and beneficiary category into consideration.  Also, one report found that confounding 
by smoking and aspirin use is “unlikely to materially alter estimates of associations 
between MI and use of prescription NSAIDs” (Velentgas, Cali, Diedrick, Heinen, et al., 
2001).    
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a. Aspirin and Other OTCs  
 Additionally, concurrent use of aspirin which may decrease patient risk 
was not considered.  Aspirin has been found to modify the risk of MI associated with the 
current use of rofecoxib at low doses, by eliminating the excess risk (versus patients not 
taking rofecoxib), but aspirin was found not to reduce the excess risk in patients taking 
rofecoxib at high doses (Levesque et al., 2005).  Aspirin was found not to modify the 
risks associated with traditional NSAIDs or celecoxib and the association with 
meloxicam was indeterminate (Garcia Rodriguez et al., 2004; Levesque et al., 2005).  
Even in studies that do try to account for concurrent medication use, the possibility exists 
that over-the counter (OTC) medication use has not been accurately captured and remains 
unaccounted for.  It was not expected that OTC medication use would be different across 
the different NSAID study medications, and Velentgas et al. (2001) support this 
conclusion.   
b. Socioeconomic Factors 
 Information on potential confounding factors such as obesity, family 
history, physical activity, smoking status and socioeconomic status was not available, 
which may have introduced bias if there was an uneven distribution of these factors 
across the various medications.  “Several studies have evaluated the potential for and 
magnitude of such bias and have demonstrated that any resulting bias would be negligible 
and directed toward the null.” (Levesque et al., 2005, p488)  Hence a decision was made 
not to consider these other factors, and to assume that the socioeconomic status of 
patients taking anti-inflammatory agents was evenly distributed among the different 
agents.   
c. Co-morbid Conditions and Indications 
  Studies that have accounted for co-morbidity have reported findings 
consistent with this report (Graham et al., 2005; Hippisley-Cox & Coupland, 2005; 
Levesque et al., 2005).  Graham et al., (2005) calculated cardiovascular risk scores based 
on a regression of a multitude of factors, including cardiovascular admissions, emergency 
room visits for cardiovascular reasons, outpatient diagnoses for tobacco use, 
cardiovascular prescription drug use, arthritis, and hormone replacement therapy.  
Extensive data on co-morbidity was not available for inclusion in this analysis.  It is also 
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thought that by comparing various NSAID users amongst themselves instead of to non-
users, confounding by indication may be reduced (Juni et al., 2004).  
d. Intermittent Use 
The results are potentially confounded by the intermittent nature of use of 
this class of medications.  Also, patients taking NSAIDs tend to try several different 
agents to find what they prefer best (Levesque et al., 2005).  A thirty-day grace period 
was used in an attempt to account for this effect, but for those patients with multiple 
prescriptions, there is no way of actually knowing what was or was not being taken at the 
time of the event. The assumption was made that the most recently acquired prescription 
was likely being taken at the time of the event.  Other studies differ in their classification 
of current or previous use and the classifications for use in this study are intermediate 
(Graham et al., 2005; Hippisley-Cox & Coupland, 2005; Kimmel et al., 2005; Levesque 
et al., 2005).  Also, the dosage calculations are based on physician directions and 
quantities ordered, which are not necessarily consistent with how the patient actually took 
the medication. 
3. Event Selection 
It was assumed that the earliest recorded event date was the first occurrence of the 
event.  All patients with an event date earlier than January 1, 2002 were discarded.  This 
may not have been the case in reality. It is possible, though not likely, that the patient had 
an initial event that was not recorded in the TRICARE system and the current event was 
not actually the first.  Another issue was the fact that patients could be admitted to the 
nearest civilian medical facility and then subsequently transferred to a military facility for 
further care.  This would possibly show up as two separate events when it is indeed only 
one.  This too supported use of the earliest event date.  A second issue with coding is that 
all strokes were considered as events and they were not differentiated by classification as 
hemorrhagic versus ischemic.  Ischemic events would be expected in the COX-2 
medications while due to the antiplatelet activity of naproxen, hemorrhagic strokes could 
have been more likely. 
Validity of use of the ICD-9, 410, in the primary diagnosis field for determination 
of MI’s as an event has previously been established at positive predictive values of 92% 
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and 95% although these results may not be representative of the particular database used 
in this study (Graham et al., 2005; Levesque et al., 2005).  Evidence was not found as to 
the validity of the ICD-9 classifications of stroke.  It was assumed that the diagnoses 
were reasonably accurate and there were no differences in accuracy among the patients 
using the different medications.    
4. Data Issues 
a. ID Mapping 
In order to preserve patient privacy and identities, the ID numbers were 
mapped and encoded to pseudoID’s.  The M2 database recorded information according to 
the patient’s social security number prior to June 2003 and then used a Defense 
Enrollment Eligibility Reporting System (DEERS) number following that date to record 
information.  Mapping both the social security and the DEERS enrollment number to one 
presented some difficulties in that not all would match properly, resulting in loss of 
26,627 potential event records. 
b. Size of Data 
The two main data files containing the prescription information and event 
information were more than 800 megabytes, presenting issues with data management and 
statistical analysis.  S-Plus 7.0 was used to process the data with functionality found in 
the BD Library.  The BD Library was in an early stage of release and the commands in 
the BD Library did not always match up with or provide the same functionality as 
standard commands and functions.   
A more thorough analysis that attempted to better account for confounders 
could have been attempted, but this would have required more or less continual access to 
the M2 database and extensive effort on the part of PEC personnel who were gracious 
enough to pull the requested data.  Data size was also prohibitive for the use of 
partitioning functions in order to determine age bins or dosing categorization more 
efficiently.  Addition of interaction terms also proved to be computationally prohibitive.  
c. Data Integrity 
Assessment of the distribution of patients in beneficiary categories and age 
bins provided evidence of misclassifications.  Age category analysis indicated that there 
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were 2 patients over the age of 115 and that they were taking ibuprofen at the maximum 
dosage.  These individuals were removed from the study, since the data was presumed to 
be inaccurate.  It is possible and even likely that inaccuracy of birth dates led to more 
misclassifications of age, particularly in the last two age bins, but these instances could 
not be readily detected, were assumed to be a small percentage (less than 5%), and were 
not expected to favor any particular medication.  There was also evidence of 
misclassification of beneficiary categories since it is highly unlikely that an individual of 
age greater than 90 years is serving on active duty.  These individuals were left in the 
study for the same reasons as mentioned above.   
Tamblyn, Lavoie, Petrella and Monette (1995) conducted an investigation into the 
accuracy of pharmacy claims databases utilized in pharmacoepidemiological research 
such as this.  It was determined that the prescription claims database was an accurate 
means of determining drugs dispensed to individuals and also indicated that use of dosing 
information may have limitations.  Although the database that was assessed was the 
prescription claims database in Quebec, it is reasonable to believe that the M2 database 
possesses similar accuracy.           
C. COMPARATIVE STUDIES 
While the results in this study support some of the more recent findings where 
rofecoxib has been clearly established as having an increased risk of MI (Graham et al., 
2005; Levesque et al., 2005; Solomon et al., 2004), other fairly recent studies are not 
supported (Mamdani et al., 2003; Reicin et al., 2002).  Reicin et al. (2002) lacked power 
to detect differences due to small sample sizes, a short study period (average 3.5 months), 
and a population limited to patients with osteoarthritis.  Mamdani et al., (2003) used a 
Cox proportional hazards model, had large sample sizes, and accounted for multiple 
confounders.  However, neither of these two studies categorized dosing into high or low 
ranges or attempted to quantify exposure.  Most studies seem to be limited by different 
aspects; age of patients, post-surgery, concomitant use of aspirin, dose and stratification 
of medication use and limited selection of medication comparisons.  While some studies 
report no increased incidence of MI’s with COX-2’s or NSAID’s when compared to non-
users, they do detect a difference in risks with rofecoxib consistently having the highest 
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risk (Hippisley-Cox & Coupland, 2005; Kimmel et al., 2005). The earlier conflicting 
studies were summarized in a meta-analysis by Juni et al. (2004) in an attempt to provide 
some clarification of results, but this analysis itself is not without criticism (Horton, 
2004).  Juni et al. (2004) found that rofecoxib had a relative risk of 2.24 (95% CI 1.24-
4.02) when compared with control groups, and found that the relative risk for naproxen 
was 0.86 (95% CI 0.75-0.99).  The meta-analysis included 20,742 patients who 
experienced a total of 52 MIs.  Issues with the meta-analysis include the pooling of data 
from studies with 3 different kinds of comparators and the selective use of available data 
(Horton, 2004).  
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V. CONCLUSION AND RECOMMENDATIONS 
This study provides information for prescribing NSAIDs as safely as possible 
when considering cardiovascular risk.  It does not provide an evaluation of 
gastrointestinal risk which also must also be considered by patients and prescribers.  This 
information may be used as part of a complete cost-benefit analysis for the remaining 
agents in the NSAID category.  It supports the removal of both rofecoxib and valdecoxib 
from the market and provides direct comparisons of the remaining agents.  The data 
suggests ibuprofen and naproxen are the NSAIDs of choice when considering CV events, 
with a ranking of increasing risk as follows: ibuprofen, naproxen, meloxicam and 
celecoxib.  The difference between meloxicam and naproxen was not significant although 
the difference between meloxicam and ibuprofen was.  Also, meloxicam was found not to 
be different from both celecoxib and valdecoxib although celecoxib and valdecoxib were 
different from each other.   
The postulated theory that CV risk is a function of COX-2 inhibitory potency is 
also supported by these results (Levesque et al., 2005).  Celecoxib and meloxicam have 
been shown to possess one tenth the COX-2 inhibition potency of rofecoxib and this is 
likely the reason for significantly different CV risks.  It is possible that not differentiating 
between hemorrhagic versus ischemic strokes may have introduced bias to the naproxen 
group, since previous studies do suggest an increased CV risk with ibuprofen when 
compared to naproxen (Graham et al., 2005; Hippisley-Cox & Coupland, 2005).  
However, if the hemorrhagic events had been excluded, naproxen risk comparisons could 
only have improved.         
Although this study has weaknesses with respect to confounders, it provides a 
good basis for further investigation into the differences and relative risks of the NSAIDs 
commonly prescribed.  Classification of exposure into present users, recent users and 
previous users, or categorizing duration of use may have provided additional information 
not captured in the study model.  Additional information may also have been gained by 
accounting for prescribing indications, co-morbid disease states, and gender.  This 
information was not available for this study as access to the database was somewhat 
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limited.  Follow-up studies with this additional information may be helpful in providing 
further distinctions among this class of medications.  Also, a comparison of patients who 
did not take NSAIDs by adding a matched control group would provide additional 
information.  
It is interesting that this simple study design provided results which are generally 
consistent with recent large observational studies that accounted extensively for potential 
confounders (Graham et al., 2005; Hippisley-Cox & Coupland, 2005; Kimmel et al., 
2005; Levesque et al., 2005).  The beneficiary category variable may have acted as a 
surrogate for other potential confounders.            
While this report assumed reasonable accuracy of the database with respect to 
quantities and dosing of patients, an investigation of data integrity of the M2 database, 
such as that by Tamblyn et al. (1995), would be helpful. 
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APPENDIX A. LIST OF ACRONYMS 
COX- cyclo-oxygenase enzyme 
CV- cardiovascular 
DEERS- defense eligibility enrollment system 
FDA-Food and Drug Administration 
GI- gastrointestinal 
M2-DoD TRICARE healthcare database 
MHS- military health system 
MI- myocardial infarction 
MTF- military treatment facility 
NSAID- non-steroidal anti-inflammatory agent 
OTC- over-the-counter 

































THIS PAGE INTENTIONALLY LEFT BLANK 
  29
APPENDIX B. FDA DECISION MEMORANDUM 
MEMORANDUM  
DATE: April 6, 2005  
FROM: John K. Jenkins, M.D.  
Director, Office of New Drugs (OND)  
and  
Paul J. Seligman, M.D., M.P.H  
Director, Office of Pharmacoepidemiology and Statistical 
Science (OPaSS)  
THROUGH: Steven Galson, M.D., M.P.H.  
Acting Director, Center for Drug Evaluation and Research  
TO: NDA files 20-998, 21-156, 21-341, 21-042  
SUBJECT: Analysis and recommendations for Agency action regarding non-steroidal 
anti-inflammatory drugs and cardiovascular risk  
Executive Summary 
Following a thorough review of the available data we have reached the following 
conclusions regarding currently approved COX-2 selective and non-selective non-
steroidal anti-inflammatory drugs (NSAIDs)
1 
and the risk of adverse cardiovascular (CV) 
events:
2 
 • The three approved COX-2 selective NSAIDs (i.e., celecoxib, rofecoxib, and 
valdecoxib) are associated with an increased risk of serious adverse CV events 
compared to placebo. The available data do not permit a rank ordering of these 
drugs with regard to CV risk.  
 • Data from large long-term controlled clinical trials that have included a 
comparison of COX-2 selective and non-selective NSAIDs do not clearly 
demonstrate that the COX-2 selective agents confer a greater risk of serious 
adverse CV events than non-selective NSAIDs.  
 • Long-term placebo-controlled clinical trial data are not available to adequately 
assess the potential for the non-selective NSAIDs to increase the risk of serious 
adverse CV events.  
 • Pending the availability of additional long-term controlled clinical trial data, the 
available data are best interpreted as being consistent with a class effect of an 
increased risk of serious adverse CV events for COX-2 selective and non-
selective NSAIDs.  
 
1 
A list of the non-selective NSAIDs is available on 
http://www.fda.gov/cder/drug/infopage/cox2/default.htm.  
2 
The degree of COX-2 selectivity for any given drug has not been definitively established, and there is 
considerable overlap in in-vitro COX-2 selectivity between agents that have been generally considered to 
be COX-2 selective (e.g., celecoxib, rofecoxib, valdecoxib, parecoxib, lumiracoxib, etoricoxib) and older 
NSAIDs that have been considered to be non-selective (e.g., diclofenac, ibuprofen, naproxen). For purposes 
of simplicity of discussion and comparisons, this document maintains the traditional separation between 
COX-2 selective and non-selective agents, but our use of this nomenclature should not be considered as 
FDA endorsement of such designations.  
   • Short-term use of NSAIDs to relieve acute pain, particularly at low doses, does 
not appear to confer an increased risk of serious adverse CV events (with the exception of 
valdecoxib in hospitalized patients immediately post-operative from coronary artery 
bypass (CABG) surgery).  
 • Controlled clinical trial data are not available to rigorously evaluate whether 
certain patients derive greater relief of pain and inflammation from specific 
NSAIDs compared to others or after failing to respond to other NSAIDs.  
 • The three approved COX-2 selective drugs reduce the incidence of GI ulcers 
visualized at endoscopy compared to certain non-selective NSAIDs. Only 
rofecoxib has been shown to reduce the risk of serious GI bleeding compared to a 
non-selective NSAID (naproxen) following chronic use. The overall benefit of 
COX-2 selective drugs in reducing the risk of serious GI bleeding remains 
uncertain, as does the comparative effectiveness of COX-2 selective NSAIDs and 
other strategies for reducing the risk of GI bleeding following chronic NSAID use 
(e.g., concomitant use of a non-selective NSAID and a proton pump inhibitor).  
 • Valdecoxib is associated with an increased rate of serious and potentially life-
threatening skin reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson 
syndrome, erythema multiforme) compared to other COX-2 selective agents and 
is the only NSAID with a boxed warning for this adverse event in its approved 
package insert. In the absence of any demonstrated advantage over other NSAIDs, 
the overall benefit versus risk profile for valdecoxib is unfavorable for marketing.  
 
Based on these conclusions, we recommend the following regulatory actions to 
further improve the safe and effective use of these drugs by prescribers, patients, and 
consumers:  change footer to 1” – check all the way through 
 • The agency should ask Pfizer to voluntarily withdraw Bextra (valdecoxib) from 
the U.S. market. In the event Pfizer does not agree to a voluntary withdrawal, the 
agency should initiate the formal withdrawal procedures; i.e., issuance of a Notice 
of Opportunity for Hearing (NOOH).  
 • The professional labeling for all prescription NSAIDs should be revised to 
include a boxed warning highlighting the potential increased risk of serious 
adverse CV events. The boxed warning should also include the well described 
NSAID class risk of serious, and often life-threatening, GI bleeding, which is 
currently contained in a bolded warning.  
 • Pending the availability of additional data, the labeling for all prescription 
NSAIDs should include a contraindication for use in patients immediately post-
operative from CABG surgery.  
 • A class NSAID Medication Guide should be developed to inform patients of the 
potential increased risk of serious adverse CV events and the risk of serious GI 
bleeding.  
 • The labeling for non-prescription NSAIDs should be revised to include more 
specific information about potential CV and GI risks and information to assist 
consumers in the safe use of these drugs.  
 • The boxed warning for Celebrex (celecoxib) should specifically reference the 
available data that demonstrate an increased risk of serious adverse CV events and 
other sections of the labeling should be revised to clearly reflect these data.  
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  • The agency should carefully review any proposal from Merck for resumption of 
marketing of Vioxx (rofecoxib). We recommend that such a proposal be reviewed 
by the FDA Drug Safety Oversight Board and an advisory committee before a 
final decision is reached.  
 • The agency should request that all sponsors of non-selective NSAIDs conduct 
and submit for FDA review a comprehensive review and analysis of available 
controlled clinical trial databases to further evaluate the potential for increased 
CV risk.  
 • The agency should work closely with sponsors and other interested stakeholders 
(e.g., NIH) to encourage additional long-term controlled clinical trials of non-
selective NSAIDs to further evaluate the potential for increased CV risk.  
 
Background 
Vioxx (rofecoxib) was voluntarily withdrawn from the market by Merck in 
September 2004 following the observation of an increased risk of serious adverse CV 
events compared to placebo in a long-term controlled clinical trial. Subsequent to that 
action, reports of additional data from controlled clinical trials became available for other 
COX-2 selective NSAIDs that also demonstrated an increased risk of serious adverse CV 
events compared to placebo. These new data prompted the agency to conduct a 
comprehensive review of the available data and to present the issue for review at a joint 
meeting of FDA’s Arthritis and Drug Safety and Risk Management Advisory 
Committees on February 16-18, 2005.  
Following the joint meeting, CDER conducted a thorough internal review of the 
available data regarding cardiovascular (CV) safety issues for COX-2 selective and non-
selective non-steroidal anti-inflammatory drugs (NSAIDs). This memorandum 
summarizes the major issues considered in that review, our conclusions regarding the 
interpretation of the available data, and our recommendations for regulatory actions 
necessary to further improve the safe and effective use of these drugs by prescribers, 
patients, and consumers.  
Participants in the CDER review included staff from the Division of Anti-
Inflammatory, Analgesic, and Ophthalmologic Drug Products, the Division of Over-the-
Counter Drug Products, the Offices of Drug Evaluation II and V, the Office of New 
Drugs, the Office of Drug Safety, the Office of Biostatistics, the Office of 
Pharmacoepidemiology and Statistical Science, the Office of Medical Policy, the Office 
of Regulatory Policy, and the Office of the Center Director. Materials reviewed included 
the regulatory histories and the NDA and postmarketing databases of the various 
NSAIDs, FDA and sponsor background documents prepared for the Advisory Committee 
meeting, all materials and data submitted by other stakeholders to the Advisory 
Committee meeting, presentations made at the Advisory Committee meeting, the 
discussions held by the Committee members during the meeting, and the specific votes 
and recommendations made by the joint Committee.  
Summary of available data 
The most persuasive evidence in support of an increased risk of serious adverse 
CV effects of the COX-2 selective NSAIDs is derived from a small number of long-term 
placebo- and active-controlled clinical trials in patients with arthritis or in the disease 
prevention setting. We will briefly summarize the available data from the long-term 
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 controlled clinical trials for the three approved and two investigational COX-2 selective 
agents. We will also briefly summarize the available data from long-term controlled 
clinical trials to assess the potential for increased CV risk for the non-selective NSAIDs. 
Finally, we will briefly summarize the available data from observational studies that have 
sought to assess the potential for increased CV risk for NSAIDs. We will focus our 
discussion on the combined endpoint of death from CV causes, myocardial infarction 
(MI), and stroke, as that is a widely accepted endpoint in assessing the benefits and risks 
of a drug for CV outcomes. It should be noted that the exact definitions and adjudication 
procedures for this combined endpoint vary to some degree across the trials discussed 
below.  
Celecoxib 
The strongest data in support of an increased risk of serious adverse CV events for 
celecoxib comes from the National Cancer Institute’s Adenoma Prevention with 
Celecoxib (APC) trial in patients at risk for recurrent colon polyps. In the APC trial a 2-3 
fold increased risk of adverse CV events was seen for celecoxib compared to placebo 
after a mean duration of treatment of 33 months. There was evidence of a dose response 
relationship, with a hazard ratio
3 
of 2.5 for celecoxib 200 mg twice daily and 3.4 for 
celecoxib 400 mg twice daily compared to placebo for the composite endpoint of death 
from CV causes, myocardial infarction (MI), or stroke.  
The results from the APC trial were not replicated, however, in the nearly 
identical Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial. Based on 
preliminary, unpublished data presented by the PreSAP investigators at the AC meeting, 
the hazard ratio was 1.1 for celecoxib 400 mg once daily compared to placebo for the 
composite endpoint of death from CV causes, MI, or stroke. It is worth noting that the 
dosing interval differed between the APC trial (twice daily) and the PreSAP trial (once 
daily), although both trials included a total daily dose of celecoxib of 400 mg. It remains 
unclear what, if any, role this difference in dosing interval may have played in the 
disparate findings between the two trials.  
Another long-term controlled clinical trial of celecoxib versus placebo, the 
National Institute of Aging’s Alzheimer’s Disease Anti-Inflammatory Prevention Trial 
(ADAPT) in patients at risk for Alzheimer’s disease, also does not appear to have shown 
an increased risk for celecoxib 200 mg twice daily compared to placebo for the composite 
endpoint of death, MI, or stroke. Preliminary, unpublished data shared with FDA by the 
ADAPT investigators showed no increased relative risk for celecoxib compared to 
placebo.
4 
Finally, there was a small one-year trial comparing celecoxib 200 mg twice 
daily to placebo in patients with Alzheimer’s disease that did not demonstrate a 
significantly increased risk of serious adverse CV events, but did show a trend toward 
more CV events in the celecoxib treatment arm.  
 
3 
The hazard rate is a measure of risk per unit of time in an exposed cohort (e.g., the event rate per 
month). The hazard ratio is the ratio of the hazard rates from the treatment group relative to the control 
group, and is often used to represent the relative risk when the relative risk is constant over time.  
Is this a footnote?? 
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 The only available data from a long-term comparison of celecoxib to non-
selective NSAIDs come from the Celebrex Long-Term Arthritis Safety Study (CLASS) 
in which celecoxib 400 mg twice daily was compared to diclofenac and ibuprofen in 
approximately 8000 patients with osteoarthritis or rheumatoid arthritis. No differences 
were observed for serious adverse CV events between celecoxib and the two non-
selective NSAID comparators in this trial.  
The ADAPT trial also included naproxen as an active control and will provide an 
additional comparison of celecoxib to a non-selective NSAID when the final study results 
become available. Preliminary, unpublished data shared with FDA by the ADAPT 
investigators showed that celecoxib was intermediate between placebo (lowest incidence) 
and naproxen (highest incidence) for the composite endpoint of death, MI, or stroke.  
Rofecoxib 
The strongest data from a long-term placebo-controlled trial for an increased risk 
of serious adverse CV events with rofecoxib come from the Adenomatous Polyp 
Prevention on Vioxx (APPROVe) trial in which rofecoxib 25 mg once daily was 
compared to placebo for up to three years. A relative risk of approximately two was seen 
for rofecoxib compared to placebo for serious adverse CV events. It is noteworthy that 
the rofecoxib and placebo CV event curves in a Kaplan-Meier plot did not appear to 
begin to separate until after approximately 18 months of treatment. In contrast to the 
results seen in APPROVe, two long-term placebo-controlled trials in patients with early 
Alzheimer’s disease, including up to four years of treatment in a small number of 
patients, did not show a significant difference in CV events between rofecoxib 25 mg 
once daily and placebo.  
The only long-term controlled clinical trial comparison of rofecoxib to a non-
selective NSAID comes from the Vioxx GI Outcomes Research (VIGOR) trial in which 
rofecoxib 50 mg once daily was compared to naproxen for up to 12 months. In VIGOR, 
rofecoxib was associated with a hazard ratio of approximately two compared to naproxen 
based on the composite endpoint of death, MI, or stroke. In contrast to the findings in 
APPROVe, in VIGOR the Kaplan-Meier CV event curves for rofecoxib and naproxen 
began to separate after approximately two months of treatment.  
4 
Relative risk is defined as the cumulative risk in the treatment group (e.g., number of events per 
the number of individuals in this group) divided by the cumulative risk in the control group. The term 
relative risk is often used interchangeably with the hazard ratio. Footnote? Check all the way through 
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 Valdecoxib 
No long-term controlled clinical trials have been conducted comparing valdecoxib to 
either placebo or non-selective NSAIDs. Data are available from two short-term placebo-
controlled trials of early dosing with intravenous parecoxib (a pro-drug for valdecoxib) 
followed by oral valdecoxib in patients immediately post-operative from coronary artery 
bypass graft (CABG) surgery. In both studies, valdecoxib was associated with an 
approximately two-fold increased risk of serious adverse CV events compared to placebo. 
In contrast, a short-term placebo-controlled trial of intravenous parecoxib followed by 
oral valdecoxib in patients undergoing various types of non-vascular general surgical 
procedures showed no differences for serious adverse CV events.  
Investigational COX-2 Selective Agents 
Data from long-term controlled clinical trials are also available for two 
investigational COX-2 selective agents (lumiracoxib and etoricoxib), and were presented 
at the AC meeting. These data are summarized here as they provide further insights 
regarding the issue of CV risk for COX-2 selective agents and the comparison of CV 
risks between COX-2 selective drugs and non-selective NSAIDs.  
The Therapeutic COX-189 Arthritis Research and Gastrointestinal Event Trial 
(TARGET) compared lumiracoxib 400 mg once daily to naproxen and ibuprofen for one 
year in approximately 18,000 patients with osteoarthritis. TARGET was designed as two 
sub-studies and the planned primary analysis was to be the combined lumiracoxib groups 
compared to the combined naproxen and ibuprofen groups. The study design, however, 
did not clearly reflect this intent since randomization occurred at the sub-study level 
rather than across the entire study. For reasons that are not entirely clear, but possibly 
related in part to the randomization schema, the event rates for serious adverse CV events 
in the lumiracoxib groups in the two sub-studies were very different, i.e., 1.1 events per 
100 patient years in the naproxen sub-study versus 0.58 events per 100 patient years in 
the ibuprofen sub-study. The event rates for serious adverse CV events for naproxen and 
ibuprofen were very similar in the two sub-studies; i.e., 0.76 events per 100 patient years 
for naproxen and 0.74 events per 100 patient years for ibuprofen.  
The pre-specified primary analysis of TARGET found no difference in serious 
adverse CV events between the combined lumiracoxib groups and the combined 
naproxen and ibuprofen groups. The validity of combining the two lumiracoxib groups 
for purposes of the primary analysis is debatable, however, given the study design and the 
very different lumiracoxib event rates in the two sub-studies. It is unfortunate that the 
study design did not call for randomization of treatment assignment across the entire 
study, which would have allowed for a much more powerful comparison of lumiracoxib 
to the two non-selective NSAIDs.  
Given the study design, the data from TARGET have also been analyzed by sub-
study. In the naproxen sub-study, a hazard ratio of 1.44 was observed for the comparison 
of lumiracoxib and naproxen for serious adverse CV events. In the ibuprofen sub-study, a 
hazard ratio of 0.79 was observed for the comparison of lumiracoxib and ibuprofen for 
serious adverse CV events. The observed differences between lumiracoxib and the 
NSAID comparators were not statistically significantly different in either sub-study.  
Depending on which analysis of the TARGET study one considers, the conclusions may 
be very different. The pre-specified primary analysis would suggest that lumiracoxib, a 
highly COX-2 selective agent, is indistinguishable from two non-selective agents with 
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 regard to the risk of serious adverse CV effects. The sub-study results, however, would 
suggest that lumiracoxib may be associated with a slightly increased CV risk compared to 
naproxen and a slightly decreased CV risk compared to ibuprofen. The cross sub-study 
comparison of naproxen and ibuprofen, however, would suggest no difference in CV risk 
for these non-selective NSAIDs. Overall, this study does not support a clear distinction 
between lumiracoxib and the non-selective NSAIDs.  
The Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and 
Effectiveness Trial (EDGE) compared etoricoxib 90 mg once daily versus diclofenac for 
up to 16 months in approximately 7100 patients with osteoarthritis. The relative risk for 
serious adverse CV events was 1.07 for the comparison of etoricoxib to diclofenac (not 
significantly different). EDGE, therefore, is another large controlled clinical trial that did 
not distinguish COX-2 selective and non-selective NSAIDs with regard to CV risk.  
Non-selective NSAIDs 
Long-term placebo- and active-controlled trials are generally not available for the 
non-selective NSAIDs, with the exception of the studies noted above where certain non-
selective NSAIDs were used as active controls in studies of COX-2 selective drugs.  
Observational studies 
Data are available from a number of published and unpublished observational 
studies to address the issue of increased risk of serious adverse CV events for COX-2 
selective and non-selective NSAIDs. These studies have utilized a variety of designs, 
methods, source databases, and comparison groups, and each study has been 
characterized by strengths and weaknesses. In most of the observational studies, the 
estimated relative risks of the COX-2 selective NSAIDs have ranged from 0.8 to 1.5, 
with many point estimates not achieving statistical significance. These data were 
presented and discussed in detail at the AC meeting and the committee members 
generally agreed that the observational data could not definitively address the question of 
a modestly increased CV risk for the COX-2 selective compared to the non-selective 
NSAIDs, with the possible exception of data on rofecoxib 50 mg.  
Overall, the most consistent finding for increased CV risk was observed for 
rofecoxib 50 mg, where statistically significant relative risks of approximately 2 and 3 
were seen in two studies. The signal for increased CV risk for the 25 mg rofecoxib dose, 
however, was smaller and did not consistently achieve statistical significance. The 
relative risks in the seven observational studies for celecoxib ranged from 0.4 to 1.2, with 
statistical significance observed once for a lowered risk and once for a higher relative 
risk.  The available data for the non-selective NSAIDs from the observational studies are 
limited, and no consistent signals were observed.  
Analysis and Conclusions  
As noted above, the most persuasive evidence in support of an increased risk of 
serious adverse CV effects of the COX-2 selective NSAIDs is derived from a small 
number of long-term placebo- and active-controlled clinical trials in patients with arthritis 
or in the disease prevention setting. The data from these trials, however, are not 
consistent in demonstrating an increased risk of serious adverse CV effects for COX-2 
selective drugs. Perfect replication of study results cannot be expected, and is not 
required to reach a valid scientific conclusion. However, the degree of inconsistency 
observed in the data from long-term controlled clinical trials has a considerable impact on 
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 our ability to reach valid conclusions about the absolute magnitude of increased risk and 
to make risk versus benefit determinations for particular doses of specific drugs.  
The data from controlled clinical trial comparisons of COX-2 selective and non-
selective NSAIDs do not clearly demonstrate an increased relative risk for the COX-2 
selective drugs, despite the substantial size of these studies. Only VIGOR clearly 
indicates such a difference with CLASS and EDGE giving no suggestion of a difference 
and TARGET giving analysis-dependent results. These findings, and the absence of any 
long-term placebo- or active-controlled clinical trials for most of the non-selective 
NSAIDs, make it difficult to conclude that the COX-2 selective drugs as a class have 
greater CV risks than non-selective NSAIDs. The data from the well-controlled 
observational trials also have not provided consistent assessments of risk when 
comparing COX-2 selective and non-selective NSAIDs. The point estimates of the 
relative risk comparisons from these data are mostly in a range where interpretation may 
be difficult and influenced by uncontrolled residual confounding or biases often inherent 
in the design and data limitations of these studies  
Despite the limitations of the available data, overall, there is evidence, principally 
from a small number of placebo-controlled trials, that the approved COX-2 selective 
NSAIDs (i.e., celecoxib, rofecoxib, valdecoxib) are associated with an increased risk of 
serious adverse CV events (e.g., MI, stroke, and death). It remains unclear, however, that 
it is the presence of, or the degree of, COX-2 selectivity that accounts for these 
observations, as some have hypothesized. As noted above, in various controlled clinical 
trials, COX-2 selective drugs have been indistinguishable from non-selective NSAIDs 
(i.e., ibuprofen, diclofenac) in studies of substantial size and duration. Further, although 
on theoretical grounds the addition of low-dose aspirin (a COX-1 inhibitor) to a COX-2 
selective drug should resolve any increased CV risk caused by COX-2 selectivity, this 
effect has not in fact been observed in several studies in which such comparisons are 
possible. Taken together, these observations raise serious questions about the so called 
“COX-2 hypothesis,” which suggests that COX-2 selectivity contributes to increased CV 
risk. It, therefore, remains unclear to what extent the COX-2 selectivity of an individual 
drug predicts the drug’s potential for an increased risk of adverse CV events compared to 
drugs that are less COX-2 selective.  
After carefully reviewing all the available data, we believe that the data are 
sufficient to support a conclusion that celecoxib, rofecoxib, and valdecoxib are associated 
with an increased risk of serious adverse CV events when compared to placebo. For 
celecoxib and rofecoxib these conclusions are primarily supported by the data from the 
APC and APPROVe trials, respectively. However, for celecoxib a nearly identical long-
term placebo-controlled trial (the PreSAP trial) and a similarly sized placebo-controlled 
trial in patients at increased risk for Alzheimer’s disease did not replicate these findings. 
For rofecoxib, other long-term placebo-controlled trials of equal or greater duration (the 
Alzheimer’s treatment trials) did not replicate the APPROVe findings. There are no long-
term placebo-controlled trial data for valdecoxib. It is difficult to know how to 
extrapolate the findings from the parecoxib/valdecoxib CABG trials to the chronic use 
situation given the significant physiologic and traumatic impact on the coronary 
vasculature during and following CABG surgery, and the systemic pro-inflammatory 
response resulting from heart-lung bypass. We believe, however, that it is reasonable 
from a public health perspective to assume that valdecoxib does not differ from the other 
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 COX-2 selective agents with regard to increased CV risk with chronic use pending the 
availability of data from long-term controlled clinical trials that would indicate otherwise.  
The long-term controlled clinical trial data comparing COX-2 selective agents 
(i.e., celecoxib, rofecoxib, lumiracoxib, etoricoxib) to non-selective NSAIDs are limited 
in number, but include several trials of very substantial size. They raise significant 
unresolved questions. First, rofecoxib 50 mg clearly appears to have an increased risk of 
serious adverse CV events compared to naproxen based on the data from the VIGOR 
trial.
5 
The absence of a placebo arm in the VIGOR trial, however, precludes a 
determination of whether chronic use of naproxen might also confer an increased risk of 
serious adverse CV events, albeit at a lower rate than rofecoxib. The VIGOR trial also 
does not provide a comparison between lower doses of rofecoxib and naproxen. Other 
controlled clinical trial data have also suggested some increased risk of serious adverse 
CV events for COX-2 selective agents versus naproxen (i.e., lumiracoxib in the naproxen 
sub-study in TARGET and etoricoxib in the NDA database); however, these studies also 
leave unresolved the question of whether naproxen is itself associated with an increased 
CV risk. The ADAPT trial is the only long-term controlled clinical trial in which a COX-
2 selective agent and naproxen have been compared to placebo. The preliminary data 
from the ADAPT trial, however, do not appear to follow the pattern of the other COX-2 
selective versus naproxen trials, showing a trend toward a higher event rate on naproxen 
compared to celecoxib and placebo (see above). Further, the cross sub-study comparison 
of naproxen and ibuprofen in TARGET suggests no difference in CV risk between these 
two non-selective NSAIDs. Taken together these data provide some support for the 
conclusion that a difference exits in the risk of serious adverse CV events between COX-
2 selective agents and naproxen, but they do not provide any assurance that naproxen 
itself confers no increased CV risk; i.e., we cannot consider naproxen to be equal to or 
better than placebo.  
The comparisons of COX-2 selective agents to certain other non-selective 
NSAIDs also raise interesting, and in the end unresolved, questions regarding the relative 
risk of COX-2 selective drugs compared to non-selective NSAIDs, despite the very large 
size of some of the trials. Several long-term controlled clinical trial comparisons of COX-
2 selective agents to diclofenac have failed to provide evidence that diclofenac has a 
lower risk of serious adverse CV events than COX-2 selective agents (e.g., versus 
celecoxib in CLASS, versus etoricoxib in the NDA database, versus etoricoxib in 
EDGE). Large, long-term controlled clinical trial comparisons of COX-2 selective agents 
to ibuprofen, an unequivocally non-selective agent, also have failed to suggest a clear 
separation with regard to the risk of serious adverse CV events (e.g., versus celecoxib in 
CLASS, versus lumiracoxib in the ibuprofen sub-study in TARGET). While even these 
large studies cannot rule out a small true difference in CV risk between COX-2 selective 
agents and diclofenac and ibuprofen, they show no clear trend and are best interpreted as 
showing that the risk of serious adverse CV events between COX-2 selective agents and 
either diclofenac and ibuprofen are in fact very similar.  The latter interpretation, taken 
together with the findings of an increased risk of serious adverse CV events from the 
long-term placebo-controlled clinical trials of COX-2 selective agents, would support 
 
5 
Rofecoxib 50 mg is not recommended for chronic use in the approved labeling for Vioxx. The 
higher dose of rofecoxib was used in the VIGOR trial to provide a “worst case” estimate of the risk of 
serious GI bleeding for rofecoxib in comparison to naproxen. 
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 a conclusion that at least some of the non-selective NSAIDs are also associated with an 
increased risk of serious adverse CV events.  
The inability to reliably estimate the absolute magnitude of the increased risk of 
serious adverse CV events for individual COX-2 agents, combined with the inability to 
reliably draw conclusions about the risk of COX-2 agents compared to one another or to 
other NSAIDs, highlights the conundrum the Agency faces in making decisions on 
appropriate regulatory actions. There is an urgent public health need to make appropriate 
regulatory decisions because the adverse events at issue are serious and a very large 
number of patients use selective and non-selective NSAIDs to treat chronic pain and 
inflammation. At the same time, erroneous conclusions and inappropriate actions are 
themselves potentially harmful to the public health. Although the currently available data 
are not definitive, the Agency cannot await more definitive data, which may take years to 
accumulate from studies that have not even begun, before taking action.  
In summary, we conclude that the three approved COX-2 selective drugs are 
associated with an increased risk of serious adverse CV events, at least at some dose, 
with reasonably prolonged use. We do not believe, however, that the currently available 
data allow for a rank ordering of the approved COX-2 selective drugs with regard to CV 
risk. We also believe that it is not possible to conclude at this point that the COX-2 
selective drugs confer an increased risk over non-selective NSAIDs in chronic use. 
Naproxen may be an exception, but the comparative data to COX-2 selective agents are 
not entirely consistent, we do not have adequate long-term placebo-controlled data to 
fully assess its potential CV risks, and the cross sub-study comparison to ibuprofen in 
TARGET does not suggest a lesser CV risk. For the vast majority of non-selective 
NSAIDs we do not have any data that allow comparisons with COX-2 selective agents 
for CV risk, and where data exist, primarily from very large studies, they do not 
consistently demonstrate that the COX-2 agents confer a greater risk. Finally, there are no 
data from long-term placebo-controlled trials for the non-selective NSAIDs (other than 
the preliminary data for naproxen from ADAPT) that are analogous to the data available 
for the COX-2 selective agents.  
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 The absence of long-term controlled clinical trial data for the non-selective 
NSAIDs significantly limits our ability to assess whether these drugs may also increase 
the risk of serious adverse CV events. The long marketing history of many of these drugs 
cannot be taken as evidence that they are not associated with an increased risk of serious 
adverse CV events since CV events occur fairly commonly in the general population and 
small increases in common adverse events are impossible to detect from spontaneous 
reporting systems. The adverse CV risk signal for the COX-2 selective drugs became 
apparent only from large, long-term controlled clinical trials and large retrospective 
cohort studies. Similar clinical trials are needed to assess the potential risks of the non-
selective NSAIDs.  
Given our inability to conclude, based on the available data, that the COX-2 
selective agents confer an increased risk of serious adverse CV events compared to non-
selective NSAIDs, we believe that it is reasonable to conclude that there is a “class 
effect” for increased CV risk for all NSAIDs pending the availability of data from long-
term controlled clinical trials that more clearly delineate the true relationships. This 
interpretation of the available data will serve to promote public health by alerting 
physicians and patients to this class concern and will make it clear that simply switching 
from a COX-2 selective agent to a non-selective NSAID does not mean that the potential 
for increased risk of serious adverse CV events has been fully, or even partially, 
mitigated.  
With a “class effect” of NSAIDs on CV risk as a baseline, other factors must be 
considered in determining the overall risk versus benefit profile for individual drugs 
within the class and what, if any, regulatory actions are appropriate. Some of the factors 
that must be considered include any demonstrated benefit of a given drug over other 
drugs in the class (e.g., superiority claims, effectiveness in patients who have failed on 
other drugs) and any unique toxicities (or absence of a toxicity) of a given drug over 
other drugs in the class.  
With regard to greater or special effectiveness, while it is widely believed that 
patients differ in their response to NSAIDs, there are no controlled clinical trial data (e.g., 
studies in non-responders to a particular NSAID) to support such conclusions. 
Nonetheless, despite the lack of rigorous evidence, this widely accepted belief is at least 
in part a valid rationale for maintaining a range of options in the NSAID class from 
which physicians and patients may choose. In addition, as noted above, there is no basis 
for concluding that the risk of serious adverse CV events for some NSAIDs is worse than 
the risk for the others, which supports maintaining a range of options.  
With regard to toxicities, the primary goal in developing COX-2 selective agents 
was to reduce the serious, and often life-threatening, risk of gastrointestinal (GI) bleeding 
associated with chronic use of all NSAIDs. To date, the only COX-2 selective agent that 
has demonstrated a reduced risk for serious GI bleeding is rofecoxib, but only in 
comparison to naproxen. All of the approved COX-2 selective agents have been shown to 
reduce the incidence of GI ulcers visualized at endoscopy compared to certain non-
selective NSAIDs, but the clinical relevance of this finding as a predictor of serious GI 
bleeding has not been confirmed (e.g., no difference in serious GI bleeding was observed 
in CLASS). Improved GI tolerability of NSAIDs is an important issue from an individual 
patient and public health perspective and is, at least in part, a valid rationale for 
maintaining a range of options in the NSAID class from which physicians and patients 
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 may choose. Besides the COX-2 selective NSAIDs, other strategies are available that 
may reduce the risk of GI bleeding with NSAIDs (e.g., combined use of a non-selective 
NSAID with misoprostol or a proton pump inhibitor), but data are currently lacking on 
how these strategies compare to the use of COX-2 selective drugs. With the exception of 
the comparison of rofecoxib to naproxen, data are not available to confirm a reduced risk 
of serious GI bleeding for the COX-2 selective agents, though it is widely believed that 
these agents are better tolerated by many patients.  
In addition to the risk of serious and potentially life-threatening GI bleeding, 
NSAIDs are also associated with other potentially serious adverse effects, including, but 
not limited to, fluid retention, edema, renal toxicity, hepatic enzyme elevation, and 
bronchospasm in patients with aspirin-sensitive asthma. Comparative data to differentiate 
NSAIDs from one another with regard to these adverse effects are generally not available 
or are inconclusive.  
Boxed warnings are currently included in the approved labeling for two single ingredient 
NSAID products.
6 
Bextra (valdecoxib) has a boxed warning for serious and potentially 
life-threatening skin reactions (i.e., toxic epidermal necrolysis, Stevens-Johnson 
syndrome, erythema multiforme). Toradol (ketorolac) has a boxed warning emphasizing 
that it is approved only for short-term (≤5 days) use in patients with moderately severe 
acute pain that requires analgesia at the opioid level, usually in a post-operative setting. 
Toradol is the only NSAID indicated for treatment of pain available for parenteral use 
(i.e., IV or IM injection); it therefore provides an important therapeutic option for 
physicians and patients in settings where the patient cannot take analgesics by mouth.
7 
This therapeutic advantage favors continued availability of Toradol, despite the need for 
a boxed warning about the potential for increased frequency of serious adverse reactions 
with long-term (≥5 days) use. In contrast, there are no data to support a unique 
therapeutic benefit for Bextra over other available NSAIDs, which might offset the 
increased risk of serious and potentially life-threatening skin reactions. While other 
COX-2 selective and non-selective NSAIDs also have a risk for these rare, serious skin 
reactions, the reported rate for these serious side effects appears to be greater for Bextra 
than for other COX-2 agents.
8 
To date, the agency has received 7 reports of deaths from 
serious skin reactions in patients following treatment with Bextra. The occurrence of 
these serious skin reactions in individual patients is unpredictable, occurring with and 
without a history of sulfa allergy (valdecoxib is a sulfonamide) and after both short- and 
long-term use, which makes attempts to manage this increased risk difficult.  
6 
The package insert for Arthrotec, a combination of diclofenac and misoprostol, includes a boxed 
warning, but the warning relates to potential toxicities of misoprostol, not diclofenac.  
7 
Indomethacin is also available as a parenteral formulation, but is only indicated for parenteral use 
for treatment of patent ductus arteriosus.  
8 
The agency has recently received a Citizens Petition regarding the risk of Stevens-Johnson 
syndrome with ibuprofen (February 15, 2005). Although the petition is currently under review, and the 
agency has not reached a decision on the requested actions, based on analyses of data obtained before the 
petition was submitted, the agency has determined that the labeling for non-prescription NSAIDs should be 
updated to warn of the potential for skin reactions. Accordingly, along with the changes to the label to 
address CV risks, the agency will ask manufacturers of non-prescription NSAIDs to make these changes. 
After we have completed our review of the petition, we may determine that additional labeling changes 
with regard to potential skin reactions are warranted. The risk for serious skin reactions is already included 
in the labeling for most prescription NSAIDs.  
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 Several non-selective NSAIDs are currently available to consumers without a 
prescription (e.g., ibuprofen, naproxen, ketoprofen). The non-prescription doses of these 
products are generally well below the maximum daily prescription doses for the same 
active ingredient and the duration of treatment without specific alternate instructions 
from a physician is limited to 10 to 14 days. The applicability of the increased risk of 
serious adverse CV events as described above from controlled clinical trials to low-dose, 
short-term use of these non-prescription products for the relief of acute pain is unclear, 
although any such risk is expected to be minimal. No signal for increased risk of serious 
adverse CV events has been detected in the short-term controlled clinical trials that 
supported the approval of these agents for treatment of acute pain. While these studies 
were primarily designed to evaluate effectiveness, the absence of a signal of increased 
CV risk provides some reassurance of the safety of short-term use. Further, with the 
exception of the parecoxib/valdecoxib CABG studies, the increased risk of serious 
adverse CV events in the controlled clinical trials described above have only become 
apparent after months to years of treatment. The parecoxib/valdecoxib data also provide 
support for the safety of short-term use. The two short-term placebo-controlled CABG 
studies showed an increased risk of serious CV events, but, a short-term placebo-
controlled trial in general surgery patients did not show an increased risk. These data may 
suggest that in the absence of a predisposing condition, such as recent CABG surgery, the 
CV risk of short-term use of NSAIDs is very small, if any, particularly at low doses and 
given the typically intermittent nature of use of non-prescription NSAIDs for relief of 
acute pain.  
Aspirin is also an NSAID that is available and widely used without a prescription. 
However, aspirin has other unique pharmacologic properties, including irreversible 
inhibition of platelet function, that distinguish it from the rest of the NSAID class. 
Further, data from long-term controlled clinical trials have clearly demonstrated that 
aspirin significantly reduces the risk of serious adverse CV events in certain patient 
populations (e.g., patients with a history of a MI). Aspirin, therefore, is an exception to 
the apparent “class effect” of increased risk for serious adverse CV events for NSAIDs 
described above. Data from large, long-term controlled clinical trials clearly showing no 
increased CV risk or a reduction in CV risk would be necessary before concluding that 
other NSAIDs are also exceptions to the class risk.  
Recommendations  
We summarize below our recommendations for appropriate regulatory actions for 
the NSAID class and select individual agents.  
NSAIDs as a class 
Boxed Warning and Contraindication  
We recommend that the professional labeling (package insert) for all prescription 
NSAIDs, including both COX-2 selective and non-selective drugs, be revised to include a 
boxed warning highlighting the potential increased risk of CV events. The boxed warning 
should also include the well described risks of serious, and often life-threatening GI 
bleeding. We believe that a boxed warning with regard to potential increased CV risk is 
an appropriate response to the currently available data and will serve to highlight to 
physicians and patients that they must carefully consider the risks and benefits of all 
NSAIDs, as well as other available options, before deciding on a treatment plan for relief 
of chronic pain and inflammation. If it is determined that chronic use of an NSAID is 
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 warranted for an individual patient, the boxed warning will help to emphasize the 
importance of using the lowest effective dose for the shortest duration possible along 
with appropriate attention to reduction of other risk factors for cardiovascular disease. 
The language of the boxed warning should be standardized across the class, with the 
exception of those situations where specific data or other information is available for an 
individual drug. In those cases, the standardized class wording should be maintained and 
the drug specific information added, including the results of any large controlled clinical 
trials.  
The recommendation for a boxed warning for potential increased risk of CV 
events is supported by the unanimous vote of the Advisory Committees (28 yes) on the 
question of whether the labeling for the non-selective NSAIDs should be modified to 
include the absence of long-term controlled clinical trial data to assess the potential CV 
effects of these drugs.
9 
While the AC did not specifically vote on a boxed warning, many 
of the committee members commented that such a warning would be an appropriate 
response given the current data. The Advisory Committees also strongly supported boxed 
warnings for the individual COX-2 selective drugs for increased CV risk.  
The recommendation that the boxed warning also include the well recognized 
serious, and often life-threatening, risk of GI bleeding associated with chronic use of 
NSAIDs is intended to further reinforce the existing bolded warning. The GI bleeding 
risk with NSAIDs is clearly consistent with our current approach to the use of boxed 
warnings, and placing this information in a boxed warning will serve to further 
emphasize this serious risk and ensure that physicians and patients keep this risk in mind 
as they are considering options for chronic therapy of pain and inflammation.  
We also recommend that the labeling for all NSAIDs include a contraindication 
for use in patients in the immediate post-operative setting following CABG surgery. Data 
are only available in this setting from valdecoxib, but we have concluded that this short-
term increased CV risk should be extrapolated to long-term use of valdecoxib. It is 
logical to also extrapolate this finding to other NSAIDs, pending the availability of other 
data that would suggest otherwise given the serious nature of the adverse events noted in 
the valdecoxib CABG study and the high-risk nature of the patients undergoing CABG 
surgery. The contraindication for NSAID use in this setting would NOT apply, however, 












There were 32 voting members of the Advisory Committees, but 4 members had left the meeting 
by the time this question was discussed.  
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Medication Guide  
We recommend that the patient labeling for all prescription NSAIDs, including 
both COX-2 selective and non-selective drugs, include a Medication Guide. The 
Medication Guide should focus on the potential increased risk of serious adverse CV 
events and the risks of serious GI bleeding. The Medication Guide will also inform 
patients of the need to discuss with their doctor the risks and benefits of using NSAIDs 
and the importance of using the lowest effective dose for the shortest duration possible if 
treatment with an NSAID is warranted. To avoid confusion and to allow for more rapid 
implementation, we recommend that the text of the Medication Guide be standardized 
across the class, following the model that was recently successfully implemented for anti-
depressants.  
Comprehensive Data Review and New Studies  
We recommend that the agency request that the sponsors of all non-selective 
NSAIDs conduct and submit for FDA review a comprehensive review and analysis of all 
available data from controlled clinical trials to further evaluate the potential risk of 
serious adverse CV events. The search and analysis strategy should be similar across 
sponsors and drugs. The agency should carefully review the data as they become 
available and take any appropriate regulatory actions based on the findings.  
The agency should also work closely with sponsors of non-selective NSAIDs and 
other stakeholders (e.g., NIH, professional associations, patient groups) to encourage the 
conduct of additional long-term controlled clinical trials of the non-selective NSAIDs to 
better evaluate the potential for increased risk of serious adverse CV events.  
Non-prescription NSAIDs 
We recommend that the NSAIDs that are currently available without a 
prescription for the short-term treatment of acute pain continue to be available to 
consumers. While this would apparently represent the first time that products that have a 
boxed warning in the prescription package insert would also be available for non-
prescription use, we believe the available data support a conclusion that short-term use of 
low doses of the available non-prescription NSAIDs is not associated with an increased 
risk of serious adverse CV events. The overall benefit versus risk profile for the non-
prescription NSAIDs remains very favorable when they are used according to the labeled 
instructions, and we believe that it is important to maintain a range of therapeutic options 
for the short-term relief of pain in the OTC market. Further, the other available non-
prescription drugs for short-term relief of pain and fever can also be associated with 
serious, and potentially life-threatening, adverse events in certain settings and patient 
populations.  
To further encourage the safe use of the non-prescription NSAIDs, we believe 
that the labeling for these products should be revised to include more specific information 
about the potential CV and GI risks, instructions about which patients should seek the 
advice of a physician before using these drugs, and stronger reminders about limiting the 
dose and duration of treatment in accordance with the package instructions unless 
otherwise advised by a physician. In addition, as noted earlier, the agency has determined 
that the labeling for non-prescription NSAIDs should be revised to warn of the potential 
for skin reactions. We also recommend that the Agency continue its current consumer 
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 education efforts regarding the safe and effective use of non-prescription pain relievers 
and that this new information be highlighted in those campaigns.  
CELEBREX ®, NDA 20-998/NDA 21-156 (celecoxib capsules) 
After carefully reviewing all the available data, we conclude that the benefits of 
celecoxib outweigh the potential risks in properly selected and informed patients. 
Therefore, we recommend that celecoxib remain available as a prescription drug with the 
revised labeling described below in addition to the NSAID class boxed warning, 
contraindication, and Medication Guide described above.  
Boxed warning and other labeling changes  
We recommend that the boxed warning for Celebrex include specific reference to 
the controlled clinical trial data that demonstrate an increased risk of serious adverse CV 
events (e.g., the APC trial). The text in the box may be brief and include a reference to 
the CLINICAL PHARMACOLOGY, Clinical Studies section of the labeling where the 
available long-term controlled clinical trial data should be described in greater detail. 
Finally, we recommend that the INDICATIONS section of the labeling be revised to 
clearly encourage physicians to carefully weigh the potential benefits and risks of 
celecoxib and other treatment options for the condition to be treated before a decision is 
made to use Celebrex, and to use the lowest effective dose for the shortest duration 
consistent with individual patient treatment goals.  
Postmarketing study commitment  
We strongly recommend that CDER request a written commitment from the 
sponsor to conduct an additional long-term study (or studies) to address the safety of 
celecoxib compared to naproxen and other appropriate active controls (e.g., other non-
selective NSAIDs, appropriate non-NSAID active comparators). CDER should be 
actively involved in the design of the trial(s) and insist on aggressive timelines for 
initiation and completion of the study(ies).  
The above recommendations are consistent with the votes and recommendations 
made by the Advisory Committees for Celebrex. The Advisory Committees were 
unanimous in their conclusion that an increased risk of cardiovascular adverse events has 
been demonstrated for celecoxib. After carefully considering all the available data, the 
Advisory Committees voted 31 yes to 1 no in response to the question: “Does the overall 
risk versus benefit profile of celecoxib support marketing in the US?” While specific 
votes were not taken on the issue of what labeling changes and other risk management 
options would be appropriate, the overwhelming majority of the Advisory Committee 
member voiced their support for a boxed warning, a Medication Guide, and 
postmarketing study commitments to further explore the long-term safety of Celebrex in 
comparison to other appropriate comparators. 
BEXTRA ®, NDA 21-341 (valdecoxib tablets)  
After carefully considering all the available data and risk management options, we 
have concluded that the overall risk versus benefit profile for Bextra is unfavorable at this 
time. We therefore recommend that Bextra be withdrawn from the U.S. market. We have 
concluded, as noted above, that Bextra has been demonstrated to be associated with an 
increased risk of serious adverse CV events in short-term CABG trials and that it is 
reasonable from a public heath perspective to extrapolate these findings to chronic use. 
The increased risk of serious adverse CV events alone, however, would not be sufficient 
to warrant withdrawal of Bextra since we have no data showing that Bextra is worse than 
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 other NSAIDs with regard to CV risk. Our recommendation for withdrawal is based on 
the fact that, in addition to this CV risk, valdecoxib already carries a boxed warning in 
the package insert for serious, and potentially life-threatening, skin reactions (e.g., toxic 
epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme) and FDA has 
received 7 spontaneous reports of deaths from these reactions. The reporting rate for 
these serious skin reactions appears to be greater for Bextra than other COX-2 selective 
agents. Further, the risk of these serious skin reactions in individual patients is 
unpredictable, occurring in patients with and without a prior history of sulfa allergy, and 
after both short- and long-term use, which makes risk management efforts difficult. To 
date, there have been no studies that demonstrate an advantage of valdecoxib over other 
NSAIDs that might offset the concern about these serious skin risks, such as studies that 
show a GI safety benefit, better efficacy compared to other products, or efficacy in a 
setting of patients who are refractory to treatment with other products.  
The recommendation that Bextra be withdrawn is supported, at least in part, by 
the specific votes and recommendations of the Advisory Committees. The Advisory 
Committees were unanimous in their conclusion that an increased risk of cardiovascular 
adverse events has been demonstrated for valdecoxib. In response to the question “Does 
the overall risk versus benefit profile of valdecoxib support marketing in the US?” the 
Advisory Committees voted 17 yes and 13 no with 2 abstentions. Several of the advisory 
committee members who voted no expressed concerns about the strong signal of CV risk 
from the CABG trials, the absence of long-term controlled trial data to more clearly 
define the potential CV risks of Bextra, the fact that Bextra already carried a boxed 
warning for serious skin reactions, and the fact that there were no data to support a 
conclusion that Bextra offered a therapeutic advantage over NSAIDs.  
One potential argument in favor of continued marketing of valdecoxib is that it 
provides an additional therapeutic option for management of arthritis and that prescribers 
and patients could be informed of the potential increased risk of CV events and serious 
GI bleeding, in addition to the potential for serious and possibly life-threatening skin 
reactions, and be allowed to make individualized treatment decisions. This approach, in 
fact, was strongly favored by practicing rheumatologists on the Advisory Committee. It is 
important to note, however, that there are more than 20 other NSAIDs on the market. 
This range of options diminishes the value of continued marketing of valdecoxib, 
particularly in the face of an already existing boxed warning regarding serious, and 
potentially life-threatening, skin reactions and the fact that there are no data that 
demonstrate that valdecoxib offers any therapeutic advantage over other NSAIDs.  
We recommend that FDA request that Pfizer voluntarily withdraw Bextra from 
the U.S. market. If Pfizer does not agree to that request, we recommend that FDA initiate 
the formal withdrawal process by preparing and publishing a Notice of Opportunity for 
Hearing.  
We recommend that FDA remain open to allowing limited access to valdecoxib 
under an IND to those patients who believe that it is their best option, if the sponsor 
proposes such an IND. If additional clinical trials subsequently demonstrate that 
valdecoxib does not have an increased CV risk (or if its risk is significantly less than 
other available agents) or a therapeutic advantage for valdecoxib over other NSAIDs, 
FDA should carefully consider those data and reassess the current conclusions regarding 
the overall risks and benefits for valdecoxib.  
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 VIOXX ®, NDA 21-042 (rofecoxib tablets and oral suspension) 
VIOXX was voluntarily withdrawn from the U.S. market by the sponsor on 
September 30, 2004, following the announcement of the results from the APPROVe trial. 
Therefore, no regulatory action is warranted at this time. Should the sponsor seek to 
resume marketing for rofecoxib, a supplemental NDA with revised labeling will be 
required. The supplemental NDA would require FDA review and approval prior to 
implementation of the new labeling since the changes would not be of the type allowed 
under FDA regulations for a “Changes Being Effected (CBE)” labeling supplement The 
supplemental application should specifically outline the sponsor’s proposal for revised 
labeling designed to provide for safe and effective use of the drug in populations where 
the potential benefits of the drug may outweigh potential risks, and all data and 
arguments that support resumption of marketing.  
We believe that FDA should carefully review any such proposal submitted by the 
sponsor. We would also recommend that the FDA Drug Safety Oversight Board (DSB) 
and an advisory committee be consulted before a final decision is taken. Our rationale for 
recommending review by the DSB and an advisory committee includes the following 
factors. First, there is limited precedent for a drug that has been withdrawn from the U.S. 
market for safety reasons to be returned to marketing. The only recent example that we 
can recall was Lotronex, and that application was reviewed by an advisory committee 
before FDA reached a final decision on the sponsor’s request.
10 
Second, concerns were 
expressed at the recent advisory committee meeting that Vioxx may be associated with a 
higher risk of increased blood pressure, fluid retention, and congestive heart failure than 
other COX-2 selective NSAIDs. We believe that these additional potential serious risks 
of Vioxx need to be fully explored through a public process before a decision is made 
regarding resumed marketing. Third, the recent advisory committee meeting was a 
general issues meeting, not one specifically devoted to the issue of resumption of 
marketing of Vioxx. While the committees narrowly voted in the affirmative that the 
overall risk versus benefit profile of rofecoxib supported marketing in the U.S., the 
committee members expressed a wide variety of often contradictory opinions on what 
regulatory actions (e.g., labeling changes, risk management efforts) would be appropriate 
to allow resumed marketing. Specific votes were not taken on these important issues, and 
we believe the agency would benefit from the advice of an advisory committee meeting 
specifically devoted to the resumption of marketing of Vioxx before the FDA reaches a 
decision on final action. Finally, the withdrawal of Vioxx has been the subject of intense 
public interest and debate, and we believe that a transparent process for reaching an 
agency decision on resumption of marketing is needed to ensure public confidence in the 
agency’s decision-making process.  
 
10 
The FDA Drug Safety Oversight Board had not been established at the time of the review of the 









APPENDIX C. NUMBER OF PRESCRIPTIONS BY AGE AND 
DOSING  
Dosing by Medication and Age Bin 
  [41.28,46.78) [46.78,52.27) [52.27,57.77) [57.77,63.26) 
Med Low High Low High Low High Low High 
% COX-2 29.3 38.3 50.4 59.2 
Valdecoxib 31493 4671 46558 5735 62399 6441 81151 6876 
Celecoxib 61926 28341 100618 48903 136127 71143 172699 90822 
Meloxicam 30196 1328 39285 1672 46028 1887 54803 1963 
Ibuprofen 101648 241217 105151 243261 78397 184072 65971 140582 
Naproxen 147306 14467 157100 16297 132597 15569 118144 14574 
Rofecoxib 74941 21080 117080 30429 155651 34799 187625 36540 
  [63.26,68.75) [68.75,74.25) [74.25,79.74) [79.74,85.23) 
Med Low High Low High Low High Low High 
%COX-2 66.6 71.9 74.6 78.8 
 Valdecoxib 116166 8246 142930 7776 104321 5079 76104 2784 
Celecoxib 253139 120300 303508 130174 241625 92606 196770 63748 
Meloxicam 65041 2199 66646 2046 48400 1426 33379 832 
Ibuprofen 67622 125013 66139 97216 47595 54648 31530 27701 
Naproxen 124178 15758 111631 14252 73912 8951 42074 4903 
Rofecoxib 256400 41808 293641 38301 221913 25191 165578 15706 
  [85.23,90.73) [90.73,107.21] 
Med Low High Low High 
%COX-2 81.1 84.5 
Valdecoxib 26324 712 5113 131 
Celecoxib 75720 21468 17817 4067 
Meloxicam 10913 235 1735 27 
Ibuprofen 10866 8047 2366 1210 
Naproxen 13012 1337 2012 267 
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APPENDIX D. ESTIMATED COEFFICIENTS FOR THE 
LOGISTIC REGRESSION MODEL 
 
Coefficients: 
 Value Std Error Z value
(Intercept) -8.716 0.130 -67.106
Celecoxib -0.066 0.032 -2.063 
Meloxicam -0.072 0.049 -1.474 
Ibuprofen -0.238 0.041 -5.853 
Naproxen -0.171 0.041 -4.140 
Rofecoxib 0.09 0.032 2.802 
High Dose 0.039 0.024 1.618 
Age 02 0.475 0.103 4.584 
Age 03 0.888 0.100 8.878 
Age 04 1.333 0.098 13.670 
Age 05 1.670 0.096 17.476 
Age 06 1.999 0.095 21.125 
Age 07 2.298 0.095 24.242 
Age 08 2.622 0.095 27.592 
Age 09 2.753 0.098 28.042 
Age 10 3.033 0.111 27.283 
BENCATDA -0.125 0.174 -0.716 
BENCATDGR 0.060 0.275 0.217 
BENCATDR 0.272 0.122 2.223 
BENCATDS 0.441 0.124 3.562 
BENCATGRD 0.122 0.188 0.650 
BENCATIGR -4.803 223.216 -0.022 
BENCATOTH 0.045 0.514 0.088 
BENCATRET 0.715 0.122 5.850 
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